卡瑞利珠单抗联合化疗对中晚期NSCLC患者血清肿瘤标志物的影响及其抗血管生成作用  

The Effect of Combination Chemotherapy with Carilizumab on Serum Tumor Markers and Its Anti Angiogenic Effect in Patients with Advanced NSCLC

作　　者：陈鹏涛[1] 饶鸿艳 张钱永 邱文斌[1] CHEN Pengtao;RAO Hongyan;ZHANG Qianyong;QIU Wenbin(Department of Oncology,Fuding Hospital,Fuding 350052,FujianProvince,China)

机构地区：[1]福鼎市医院肿瘤内科,福建福鼎350052

出　　处：《中国实用乡村医生杂志》2024年第12期47-50,共4页Chinese Practical Journal of Rural Doctor

摘　　要：目的 研究卡瑞利珠单抗联合化疗对中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清肿瘤标志物水平的影响及其抗血管生成作用。方法 回顾性收集2020年1月—2023年12月在福鼎市医院接受治疗的50例中晚期NSCLC患者,按照治疗方案分为对照组27例(接受化疗)和联合组23例(接受卡瑞利珠单抗联合化疗)。比较两组患者的临床疗效、血清肿瘤标志物、血管生成指标和不良反应。结果 联合组客观缓解率高于对照组,差异有统计学意义(P<0.05)。联合组细胞角蛋白19的可溶性片段21-1、癌坯抗原、鳞状细胞癌抗原、糖类抗原125低于对照组,差异有统计学意义(P<0.05)。联合组血管内皮生长因子、基质金属蛋白酶-9、碱性成纤维生长因子、血小板衍生生长因子低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论 卡瑞利珠单抗联合化疗可有效提升中晚期NSCLC治疗效果,降低肿瘤标志物水平,抑制肿瘤血管生成,且安全性良好。Objective To study the effect of combination therapy with carilizumab on serum tumor marker levels and its anti angiogenic effect in patients with advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on 50 patients with advanced NSCLC who received treatment at Fuding Hospital from January 2020 to December 2023.According to the treatment plan,they were divided into a control group of 27 patients(receiving chemotherapy)and a combination group of 23 patients(receiving combination chemotherapy with carilizumab).The clinical efficacy,serum tumor markers,angiogenesis indicators,and adverse reactions between two groups of patients were compared.Results The objective response rate of the combined group was higher than that of the control group(P<0.05).The cytokeratin 19 fragment antigen 21-1,carcinoembryonic antigen,squamous cell carcinoma antigen,and carbohydrate antigen 125 in the combined group were lower than those in the control group(P<0.05).The vascular endothelial growth factor,matrix metalloproteinase-9,basic fibroblast growth factor,and platelet-derived growth factor in the combined group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of carilizumab and chemotherapy can effectively improve the treatment efficacy of advanced NSCLC,reduce tumor marker levels,inhibit tumor angiogenesis,and have good safety.

关 键 词：非小细胞肺癌 卡瑞利珠单抗 化疗 肿瘤标志物 血管生成 

分 类 号：R734.2[医药卫生—肿瘤]